Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 1件: KIT 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
2 Acute myeloid leukemia 💬
 1件: KIT 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
3 Acute myeloid leukemia 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
4 Acute myeloid leukemia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
5 Acute myeloid leukemia 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
6 Adherens junction 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
7 Adherens junction 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
8 Adherens junction 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
9 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
10 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
11 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
12 Adrenergic signaling in cardiomyocytes 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
14 Alanine, aspartate and glutamate metabolism 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
15 Aldosterone synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
16 Alzheimer disease 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
17 Alzheimer disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
18 Alzheimer disease 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
19 Alzheimer disease 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
20 AMPK signaling pathway 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
21 AMPK signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
22 AMPK signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
23 AMPK signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
24 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
25 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
26 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
27 Apelin signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
28 Apelin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
29 Apelin signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
30 Arachidonic acid metabolism 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
31 Autophagy - animal 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
32 Autophagy - animal 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
33 Autophagy - animal 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
34 Autophagy - other 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
35 Autophagy - other 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
36 Autophagy - other 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
37 Axon guidance 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
38 Axon guidance 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
39 Axon guidance 💬
 2件: ABL1, SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
40 Bacterial invasion of epithelial cells 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
41 beta-Alanine metabolism 💬
 3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
42 Bile secretion 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
43 Bladder cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
44 Bladder cancer 💬
 1件: FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
45 Bladder cancer 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
46 Bladder cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
47 Breast cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
48 Breast cancer 💬
 2件: FGFR1, FLT4 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
49 Breast cancer 💬
 1件: KIT 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
50 Breast cancer 💬
 1件: KIT 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
51 Breast cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
52 Breast cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
53 Breast cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
54 Butanoate metabolism 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
55 C-type lectin receptor signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
56 C-type lectin receptor signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
57 Calcium signaling pathway 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
58 Calcium signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
59 Calcium signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
60 Calcium signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
61 Calcium signaling pathway 💬
 1件: HRH1 💬 D00364 💬 Loratadine 4件: 13, 46, 89, 98 💬
62 Calcium signaling pathway 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
63 Calcium signaling pathway 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
64 Calcium signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
65 cAMP signaling pathway 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
66 cAMP signaling pathway 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
67 cAMP signaling pathway 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
68 Cell cycle 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
69 Cell cycle 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
70 Cell cycle 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
71 Cellular senescence 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
72 Cellular senescence 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
73 Cellular senescence 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
74 Central carbon metabolism in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
75 Central carbon metabolism in cancer 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
76 Central carbon metabolism in cancer 💬
 2件: KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
77 Central carbon metabolism in cancer 💬
 2件: KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
78 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
79 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
80 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
81 cGMP-PKG signaling pathway 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
82 Chemical carcinogenesis - DNA adducts 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
83 Chemical carcinogenesis - reactive oxygen species 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
84 Chemical carcinogenesis - reactive oxygen species 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
85 Chemical carcinogenesis - reactive oxygen species 💬
 2件: ABL1, SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
86 Chemical carcinogenesis - reactive oxygen species 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
87 Chemical carcinogenesis - reactive oxygen species 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
88 Chemical carcinogenesis - receptor activation 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
89 Chemical carcinogenesis - receptor activation 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
90 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
91 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
92 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
93 Chemical carcinogenesis - receptor activation 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
94 Chemical carcinogenesis - receptor activation 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
95 Chemokine signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
96 Choline metabolism in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
97 Choline metabolism in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
98 Choline metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
99 Choline metabolism in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
100 Choline metabolism in cancer 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
101 Choline metabolism in cancer 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
102 Choline metabolism in cancer 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
103 Chronic myeloid leukemia 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
104 Chronic myeloid leukemia 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
105 Chronic myeloid leukemia 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
106 Circadian entrainment 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
107 Colorectal cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
108 Colorectal cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
109 Colorectal cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
110 Colorectal cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
111 Coronavirus disease - COVID-19 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
112 Cortisol synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
113 Cushing syndrome 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
114 Cushing syndrome 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
115 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
116 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
117 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
118 EGFR tyrosine kinase inhibitor resistance 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
119 EGFR tyrosine kinase inhibitor resistance 💬
 5件: FGFR2, FGFR3, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
120 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
121 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
122 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
123 EGFR tyrosine kinase inhibitor resistance 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
124 EGFR tyrosine kinase inhibitor resistance 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
125 EGFR tyrosine kinase inhibitor resistance 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
126 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
127 Endocrine resistance 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
128 Endocrine resistance 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
129 Endocrine resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
130 Endocrine resistance 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
131 Endocrine resistance 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
132 Endocytosis 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
133 Endocytosis 💬
 3件: FGFR2, FGFR3, PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
134 Endocytosis 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
135 Endocytosis 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
136 Endocytosis 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
137 Endometrial cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
138 Epithelial cell signaling in Helicobacter pylori infection 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
139 Epithelial cell signaling in Helicobacter pylori infection 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
140 ErbB signaling pathway 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
141 ErbB signaling pathway 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
142 ErbB signaling pathway 💬
 2件: ABL1, SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
143 ErbB signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
144 ErbB signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
145 ErbB signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
146 ErbB signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
147 Estrogen signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
148 Estrogen signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
149 Fluid shear stress and atherosclerosis 💬
 1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
150 Fluid shear stress and atherosclerosis 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
151 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
152 Focal adhesion 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
153 Focal adhesion 💬
 5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
154 Focal adhesion 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
155 Focal adhesion 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
156 Focal adhesion 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
157 Focal adhesion 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
158 FoxO signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
159 GABAergic synapse 💬
 3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
160 GABAergic synapse 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
161 Gap junction 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
162 Gap junction 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
163 Gap junction 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
164 Gap junction 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
165 Gap junction 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
166 Gastric acid secretion 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
167 Gastric acid secretion 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
168 Gastric cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
169 Gastric cancer 💬
 1件: FGFR2 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
170 Gastric cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
171 Gastric cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
172 Gastric cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
173 Glioma 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
174 Glioma 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
175 Glioma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
176 Glioma 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
177 Glioma 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
178 Glioma 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
179 Glioma 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
180 GnRH secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
181 GnRH signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
182 GnRH signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
183 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
184 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
185 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
186 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
187 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
188 Hematopoietic cell lineage 💬
 1件: KIT 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
189 Hematopoietic cell lineage 💬
 1件: KIT 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
190 Hepatitis B 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
191 Hepatitis C 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
192 Hepatocellular carcinoma 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
193 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
194 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
195 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
196 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
197 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
198 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
199 Herpes simplex virus 1 infection 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
200 HIF-1 signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
201 HIF-1 signaling pathway 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
202 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
203 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
204 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
205 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
206 Human cytomegalovirus infection 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
207 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
208 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
209 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
210 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
211 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
212 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
213 Human cytomegalovirus infection 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
214 Human cytomegalovirus infection 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
215 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
216 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
217 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
218 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
219 Human papillomavirus infection 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
220 Human papillomavirus infection 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
221 Human papillomavirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
222 Human papillomavirus infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
223 Human papillomavirus infection 💬
 1件: PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
224 Human papillomavirus infection 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
225 Human papillomavirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
226 Huntington disease 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
227 Huntington disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
228 Huntington disease 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
229 IL-17 signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
230 Inflammatory mediator regulation of TRP channels 💬
 1件: HRH1 💬 D00364 💬 Loratadine 4件: 13, 46, 89, 98 💬
231 Inflammatory mediator regulation of TRP channels 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
232 Insulin resistance 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
233 Insulin resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
234 Insulin resistance 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
235 Insulin signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
236 Insulin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
237 Insulin signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
238 JAK-STAT signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
239 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
240 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
241 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
242 JAK-STAT signaling pathway 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
243 JAK-STAT signaling pathway 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
244 JAK-STAT signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
245 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
246 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
247 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
248 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
249 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
250 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
251 Leishmaniasis 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
252 Lipid and atherosclerosis 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
253 Longevity regulating pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
254 Longevity regulating pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
255 Longevity regulating pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
256 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
257 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
258 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
259 MAPK signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
260 MAPK signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
261 MAPK signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
262 MAPK signaling pathway 💬
 2件: KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
263 MAPK signaling pathway 💬
 2件: KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
264 MAPK signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
265 Melanogenesis 💬
 1件: KIT 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
266 Melanogenesis 💬
 1件: KIT 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
267 Melanoma 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
268 Melanoma 💬
 3件: FGFR1, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
269 Melanoma 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
270 Melanoma 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
271 Metabolic pathways 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
272 Metabolic pathways 💬
 1件: CYP19A1 💬 D00964 💬 Letrozole 2件: 81, 89 💬
273 Metabolic pathways 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
274 Metabolic pathways 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
275 MicroRNAs in cancer 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
276 MicroRNAs in cancer 💬
 2件: ABL1, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
277 MicroRNAs in cancer 💬
 2件: ABL1, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
278 MicroRNAs in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
279 MicroRNAs in cancer 💬
 3件: FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
280 MicroRNAs in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
281 MicroRNAs in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
282 MicroRNAs in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
283 MicroRNAs in cancer 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
284 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
285 Mitophagy - animal 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
286 mTOR signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
287 mTOR signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
288 mTOR signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
289 Neuroactive ligand-receptor interaction 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
290 Neuroactive ligand-receptor interaction 💬
 1件: HRH1 💬 D00364 💬 Loratadine 4件: 13, 46, 89, 98 💬
291 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
292 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
293 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
294 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
295 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
296 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
297 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
298 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
299 Neutrophil extracellular trap formation 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
300 NF-kappa B signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
301 Non-small cell lung cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
302 Ovarian steroidogenesis 💬
 1件: CYP19A1 💬 D00964 💬 Letrozole 2件: 81, 89 💬
303 Ovarian steroidogenesis 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
304 Oxytocin signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
305 Oxytocin signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
306 Oxytocin signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
307 Pancreatic cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
308 Pancreatic cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
309 Pancreatic cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
310 Pancreatic cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
311 Pancreatic cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
312 Parathyroid hormone synthesis, secretion and action 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
313 Parathyroid hormone synthesis, secretion and action 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
314 Pathogenic Escherichia coli infection 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
315 Pathogenic Escherichia coli infection 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
316 Pathogenic Escherichia coli infection 💬
 2件: ABL1, SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
317 Pathways in cancer 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
318 Pathways in cancer 💬
 3件: ABL1, KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
319 Pathways in cancer 💬
 3件: ABL1, KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
320 Pathways in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
321 Pathways in cancer 💬
 6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
322 Pathways in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
323 Pathways in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
324 Pathways in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
325 Pathways in cancer 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
326 Pathways in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
327 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
328 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
329 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
330 Pathways of neurodegeneration - multiple diseases 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
331 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
332 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
333 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
334 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
335 Phospholipase D signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
336 Phospholipase D signaling pathway 💬
 2件: KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
337 Phospholipase D signaling pathway 💬
 2件: KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
338 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
339 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
340 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
341 Phospholipase D signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
342 PI3K-Akt signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
343 PI3K-Akt signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
344 PI3K-Akt signaling pathway 💬
 2件: KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
345 PI3K-Akt signaling pathway 💬
 2件: KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
346 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
347 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
348 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
349 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
350 Platelet activation 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
351 Prolactin signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
352 Propanoate metabolism 💬
 1件: ABAT 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
353 Prostate cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
354 Prostate cancer 💬
 4件: FGFR1, FGFR2, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
355 Prostate cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
356 Prostate cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
357 Prostate cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
358 Prostate cancer 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
359 Prostate cancer 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
360 Proteoglycans in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
361 Proteoglycans in cancer 💬
 2件: FGFR1, KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
362 Proteoglycans in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
363 Proteoglycans in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
364 Proteoglycans in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
365 Proteoglycans in cancer 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
366 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
367 Rap1 signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
368 Rap1 signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
369 Rap1 signaling pathway 💬
 2件: KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
370 Rap1 signaling pathway 💬
 2件: KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
371 Rap1 signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
372 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
373 Ras signaling pathway 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
374 Ras signaling pathway 💬
 3件: ABL1, KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
375 Ras signaling pathway 💬
 3件: ABL1, KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
376 Ras signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
377 Ras signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
378 Ras signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
379 Regulation of actin cytoskeleton 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
380 Regulation of actin cytoskeleton 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
381 Regulation of actin cytoskeleton 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
382 Regulation of actin cytoskeleton 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
383 Regulation of actin cytoskeleton 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
384 Regulation of lipolysis in adipocytes 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
385 Regulation of lipolysis in adipocytes 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
386 Relaxin signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
387 Relaxin signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
388 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
389 Renal cell carcinoma 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
390 Renin secretion 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
391 Retrograde endocannabinoid signaling 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
392 Rheumatoid arthritis 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
393 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
394 Salivary secretion 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
395 Serotonergic synapse 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
396 Shigellosis 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
397 Shigellosis 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
398 Shigellosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
399 Shigellosis 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
400 Shigellosis 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
401 Signaling pathways regulating pluripotency of stem cells 💬
 3件: FGFR1, FGFR2, FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
402 Small cell lung cancer 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
403 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
404 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
405 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
406 Steroid hormone biosynthesis 💬
 1件: CYP19A1 💬 D00964 💬 Letrozole 2件: 81, 89 💬
407 Taurine and hypotaurine metabolism 💬
 2件: GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
408 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
409 Th17 cell differentiation 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
410 Th17 cell differentiation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
411 Th17 cell differentiation 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
412 Thermogenesis 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
413 Thermogenesis 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
414 Thermogenesis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
415 Thermogenesis 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
416 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
417 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
418 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
419 Thyroid hormone signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
420 Tight junction 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
421 TNF signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
422 Transcriptional misregulation in cancer 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
423 Tuberculosis 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
424 Type I diabetes mellitus 💬
 2件: GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
425 Type II diabetes mellitus 💬
 1件: CACNA1G 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
426 Type II diabetes mellitus 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
427 Type II diabetes mellitus 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
428 Type II diabetes mellitus 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
429 Valine, leucine and isoleucine degradation 💬
 1件: ABAT 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
430 VEGF signaling pathway 💬
 1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
431 VEGF signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 10件:  2 ,  3 , 34, 46, 70, 89, 107, 161, 171, 271 💬
432 VEGF signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
433 VEGF signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
434 Viral carcinogenesis 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
435 Viral myocarditis 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
436 Viral myocarditis 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
437 Viral myocarditis 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
438 Yersinia infection 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬

先頭へ